Neurocrine Biosciences
NBIX
#1395
Rank
C$17.78 B
Marketcap
$175.66
Share price
0.52%
Change (1 day)
14.35%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2024 : C$0.35 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is C$0.35 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31C$0.56 B59.28%
2022-12-31C$0.35 B-36.44%
2021-12-31C$0.56 B6.76%
2020-12-31C$0.52 B-18.77%
2019-12-31C$0.64 B22.29%
2018-12-31C$0.52 B13.88%
2017-12-31C$0.46 B
2009-12-31C$12.13 M-35.2%
2008-12-31C$18.72 M1162.87%
2007-12-31C$1.48 M-97.63%
2006-12-31C$62.45 M-9.7%
2005-12-31C$69.16 M-12.92%
2004-12-31C$79.42 M68.05%
2003-12-31C$47.26 M277.11%
2002-12-31C$12.53 M38.33%
2001-12-31C$9.05 M56.25%
2000-12-31C$5.79 M29.68%
1999-12-31C$4.47 M-3.07%
1998-12-31C$4.61 M101.76%
1997-12-31C$2.28 M4.31%
1996-12-31C$2.19 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
C$1.03 B 195.49%๐Ÿ‡บ๐Ÿ‡ธ USA
C$10.63 B 2,926.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$0.82 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
C$43.50 B 12,278.56%๐Ÿ‡บ๐Ÿ‡ธ USA
C$99.36 B 28,173.27%๐Ÿ‡บ๐Ÿ‡ธ USA
C$93.13 B 26,398.41%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.39 B 13.46%๐Ÿ‡บ๐Ÿ‡ธ USA
C$25.97 M-92.61%๐Ÿ‡บ๐Ÿ‡ธ USA